Skip to main content

Table 4 Cox analyses of overall survival for breast cancer patients receiving NACT

From: ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc

Factors

Univariate analysis

Multivariate analysis

p-value

HR (95%CI)

p-value

HR (95%CI)

ADAM10 (Pre-NACT)

0.147

1.90 (0.80–4.52)

0.028*

3.67 (1.15–11.70)

ER

0.359

0.84 (0.57–1.23)

0.253

0.68 (0.35–1.32)

PR

0.246

0.72 (0.41–1.26)

0.982

0.99 (0.45–2.19)

HER2

0.727

0.86 (0.37–1.99)

0.531

0.73 (0.28–1.94)

Ki67

0.199

1.80 (0.73–4.43)

0.049*

3.33 (1.01–10.99)

Age

0.16

0.54 (0.23–1.28)

0.553

0.74 (0.27–2.01)

BMI

0.35

1.48 (0.65–3.36)

0.716

0.83 (0.31–2.25)

Histological grade

0.830

1.13 (0.38–3.31)

0.112

2.85 (0.78–10.37)

Tumor size

0.002**

4.11 (1.69–10.03)

0.045*

2.84 (1.02–7.88)

Distant metastasis

0.602

0.59 (0.08–4.36)

0.528

0.51 (0.06–4.15)

Lymphatic metastasis

0.011*

3.66 (1.35–9.94)

0.002**

8.13 (2.10–31.43)

Response to NACT

0.082

0.48 (0.21–1.10)

0.993

1.00 (0.38–2.67)

  1. *p < 0.05, **p < 0.01